PRESENTER: JENNIFER ALLEN, BFA, MS, LMFT, ATR-BC. This is likely all new information and a new paradigm for most therapists as it is very new to the field all together and very few therapists have been trained for this; however, the implications for therapists in the next couple of years re: how clients will be treated and how that treatment impacts the way we orient to our work will impact many therapists. In this 2-hour course, we will cover a lot of new information about the two psychedelic drugs: MDMA and psilocybin that are currently being studied with promising success for PTSD and a myriad of other mental health issues respectively. These two medicines are moving toward medical legalization rapidly. We will also touch on ketamine, which is already a legal prescription medication used for TRD. We will look at the key ingredients to positive outcomes seen in the research to date: set, setting and integration and focus on ways psychotherapy and integration are similar and different. Our country has a complicated history with psychedelics that cost us four decades of research and relief for so many who have suffered. With the tenacity of some passionate visionaries and researches—and a lot of private funding, there is a light at the end of the tunnel …and that is no hallucination!